Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Prostate cancer
ADR ID BADD_A05726
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.25      Reproductive neoplasms male malignant and unspecified
16.25.01      Prostatic neoplasms malignant
16.25.01.001      Prostate cancer
21      Reproductive system and breast disorders
21.04      Prostatic disorders (excl infections and inflammations)
21.04.02      Prostatic neoplasms and hypertrophy
21.04.02.002      Prostate cancer
Description Tumors or cancer of the PROSTATE. [MeSH]
MedDRA Code 10060862
MeSH ID D011471
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Adenocarcinoma of prostate | Ca prostate | Cancer of prostate | Carcinoma prostate | Carcinoma prostatic | Malignant neoplasm of prostate | Prostate cancer NOS | Prostate carcinoma | Prostatic cancer | Prostatic carcinoma | Prostate cancer | Progression of prostate cancer | Acinar cell carcinoma of prostate | Locally advanced prostate cancer | Advanced prostate cancer | Prostatic Neoplasms | Prostate Neoplasms | Neoplasms, Prostate | Neoplasm, Prostate | Prostate Neoplasm | Neoplasms, Prostatic | Neoplasm, Prostatic | Prostatic Neoplasm | Prostate Cancer | Cancer, Prostate | Cancers, Prostate | Prostate Cancers | Cancer of the Prostate | Prostatic Cancer | Cancer, Prostatic | Cancers, Prostatic | Prostatic Cancers | Cancer of Prostate
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D02470Nintedanib--
BADD_D02487Baricitinib0.000482%
BADD_D02490Apalutamide0.003837%
BADD_D02539Calcium0.000587%
BADD_D02548Darolutamide0.003837%
BADD_D02567Lutetium lu-177 vipivotide tetraxetan-
BADD_D02586Radium ra-223 dichloride-
BADD_D02587Relugolix0.002503%
The 3th Page    First    Pre   3    Total 3 Pages